20 completed, 5 unknown, 3 active not recruiting, 3 recruiting. 10 Phase 2, 7 Not applicable, 5 Phase 1, 1 Phase 3, 1 Phase 4.
Follow Fanconi Anemia, Complementation Group D1: new trials by email Literature Review of Fanconi Anemia, Complementation Group D1 trials Research Report on Fanconi Anemia, Complementation Group D1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC vilastobart (XTX101), Retifanlimab - Pancreatic Cancer Metastatic | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2027-01-01 | 2026-08-14 |
| Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies DSB2455 - Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency) | Phase 1 | Recruiting | Duke Street Bio Ltd | 180 | 2024-11-21 | 2026-09-02 |
| Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer Pembrolizumab, Paclitaxel, Carboplatin - Triple Negative Breast Neoplasms, Triple Negative Breast Cancer | Phase 2 | Recruiting | Okayama University | 23 | 2024-07-16 | 2025-03-20 |
| Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer Neoadjuvant Chemotherapy (NACT) - Breast Cancer (Early Breast Cancer), BRCA 1 Gene Mutation | Not applicable | Active not recruiting | N.N. Petrov National Medical Research Center of Oncology | 30 | 2022-09-27 | 2026-09-15 |
| FaCT Trial (Facilitated Cascade Testing Trial) Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing - BRCA1 Mutation, BRCA2 Mutation | Not applicable | Active not recruiting | Weill Medical College of Cornell University | 524 | 2021-07-21 | 2026-06-30 |
| Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting Prostatic Neoplasms | Completed | AstraZeneca | 205 | 2020-07-29 | 2021-12-07 | |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer Carboplatin, Olaparib - Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | Phase 2 | Recruiting | VA Office of Research and Development | 100 | 2019-10-01 | 2026-09-17 |
| Olaparib In Metastatic Breast Cancer Olaparib - Metastatic Breast Cancer, Invasive Breast Cancer | Phase 2 | Active not recruiting | Beth Israel Deaconess Medical Center | 114 | 2018-04-01 | 2026-01-05 |
| Evaluation of Tomosynthesis for Characterization and the Management of Breast Lesions Standard mammography, Standard mammography and tomosynthesis - Breast Neoplasms, Tomosynthesis | Not applicable | Unknown | Assistance Publique - Hôpitaux de Paris | 2000 | 2017-11-20 | 2017-11-24 |
| C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population Ovarian Cancer, Hereditary Ovarian Cancer Syndrome | Completed | AstraZeneca | 276 | 2015-10-28 | 2023-12-04 | |
| Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer carboplatin, olaparib - Breast Cancer, Ovarian Cancer | Phase 1 | Completed | The Netherlands Cancer Institute | 25 | 2015-05-01 | 2019-01-16 |
| Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle - Ovarian Epithelial Cancer, Carcinoma in Situ | Not applicable | Completed | Medical University of Vienna | 701 | 2013-11-01 | 2022-09-02 |
| Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests Behaviour - Cancer, Colorectal Cancer | Completed | University Hospital, Montpellier | 200 | 2012-08-01 | 2019-03-28 | |
| A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women BRCA1 Gene, BRCA2 Gene | Completed | National Cancer Institute (NCI) | 76 | 2011-06-21 | 2021-11-30 | |
| Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer Trabectedin - BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype | Phase 2 | Unknown | Catholic University of the Sacred Heart | 100 | 2011-06-01 | 2013-01-21 |
| Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ABT-767 - Fallopian Tube, Primary Peritoneal Cancer | Phase 1 | Completed | AbbVie (prior sponsor, Abbott) | 93 | 2011-05-06 | 2018-01-02 |
| Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Talazoparib - Advanced or Recurrent Solid Tumors, Breast Neoplasms | Phase 1 | Completed | Pfizer | 113 | 2011-01-03 | 2019-01-10 |
| Risk Education and Assessment for Cancer Heredity Telephone Genetic Counseling, In-Person Genetic Counseling - Breast Cancer, Ovarian Cancer | Not applicable | Completed | University of Utah | 1012 | 2009-08-01 | 2016-04-14 |
| Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer AZD2281, matching placebo - Ovarian Cancer | Phase 2 | Completed | AstraZeneca | 265 | 2008-08-28 | 2025-02-03 |
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer AZD2281, Liposomal Doxorubicin - Ovarian Neoplasms | Phase 2 | Completed | AstraZeneca | 97 | 2008-07-30 | 2019-12-05 |
Showing 20 of 33. Sign in to see all of them.
Breast Neoplasms (16) · Ovarian Neoplasms (15) · Pancreatic Neoplasms (4) · Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Fanconi Anemia, Complementation Group N (2) · Genetic Predisposition to Disease (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Anophthalmia with pulmonary hypoplasia (1) · Breast Cancer, Familial (1) · Carcinoma in Situ (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1)
Neoplasms by Site (28) · Neoplasms (25) · Endocrine Gland Neoplasms (19) · Endocrine System Diseases (19) · Genital Diseases (18) · Urogenital Diseases (18) · Urogenital Neoplasms (18) · Skin Diseases (17) · Skin and Connective Tissue Diseases (17) · Adnexal Diseases (16) · Breast Diseases (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases, Female (16) · Genital Neoplasms, Female (16)
olaparib (9) · Carboplatin (3) · ABT-767 (1) · Biopsy, Fine-Needle (1) · Cognitive Behavioral Therapy (1) · Counseling (1) · Data Collection (1) · Demography (1) · Genetic Counseling (1) · Genetic Testing (1) · Genotype (1) · Neoadjuvant Therapy (1) · Paclitaxel (1) · Secretin (1) · Standard of Care (1)
AstraZeneca (7) · National Cancer Institute (NCI) (2) · AbbVie (prior sponsor, Abbott) (1) · Assistance Publique - Hôpitaux de Paris (1) · Beth Israel Deaconess Medical Center (1) · Catholic University of the Sacred Heart (1) · Dana-Farber Cancer Institute (1) · Danish Breast Cancer Cooperative Group (1) · Duke Street Bio Ltd (1) · Johns Hopkins University (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Medical University of Vienna (1) · Memorial Sloan Kettering Cancer Center (1) · N.N. Petrov National Medical Research Center of Oncology (1)
United States (19) · Germany (6) · United Kingdom (6) · Netherlands (5) · Spain (5) · Australia (4) · Belgium (4) · Poland (4) · France (3) · Israel (3) · Sweden (3) · Austria (2) · Canada (2) · Czechia (2) · Denmark (2)
Andrew Tutt, PhD MRCP FRCR (2) · Jane Robertson, BSc, MBCHB, MD (2) · Anita Y. Kinney, R.N., Ph.D. (1) · Chanita Hughes-Halbert, Ph.D. (1) · Chi-An Chen, MD (1) · Domenica Lorusso (1) · Dr. Johann De Bono, PhD MRCP FRCR (1) · Giovanni Scambia, Prof (1) · Harshabad Singh, MBBS MD (1) · Ilse Vejborg, MD (1) · James Carmichael, BSc MBChB MD FRCP (1) · James Carmichael, BSc, MBChB, MD, FRCP (1) · Judy Garber, MD (1)
PMID 23922302, PMID 26961146, PMID 19238149, PMID 35170751, PMID 19553641, PMID 20234119, PMID 20609467, PMID 20609468, PMID 22452356, PMID 22790832, PMID 23200980, PMID 24882434, PMID 25481712, PMID 26745694, PMID 27062051, PMID 27323902, PMID 27325848, PMID 27617661, PMID 27824811, PMID 28971986, PMID 32073956, PMID 33119476, PMID 33443030, PMID 37407274, PMID 39695768, PMID 41604601, PMID 42843923
2005 (1), 2008 (1), R01CA129142 (1)